Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI 24 FE versus ISIBLOOM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI 24 FE versus ISIBLOOM.
BLISOVI 24 FE vs ISIBLOOM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and drospirenone; primarily suppresses gonadotropins (FSH, LH) via negative feedback, preventing ovulation. Drospirenone has anti-mineralocorticoid and anti-androgenic activity.
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
One tablet orally once daily for 24 weeks, followed by placebo tablets for 4 weeks; each tablet contains 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol for 21 days, then 0.01 mg ethinyl estradiol for 3 days, then 2 tablets of 75 mg ferrous fumarate for 5 days.
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
None Documented
None Documented
Drospirenone: 25-33 hours; Ethinyl estradiol: 13-24 hours; steady-state achieved after 10 days.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 30-40% as drospirenone metabolites, 20-30% as ethinyl estradiol metabolites; fecal: 40-50% as drospirenone metabolites, 30-40% as ethinyl estradiol metabolites; biliary: minimal.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Category C
Category C
Oral Contraceptive
Oral Contraceptive